Insider Selling: Entrada Therapeutics (NASDAQ:TRDA) Director Sells $73,458.00 in Stock

Key Points

• Director Kush Parmar sold 10,494 Entrada Therapeutics shares at $7.00 each, generating $73,458 and reducing his stake by 0.37% to 2.84 million shares. He has also made several other significant sales recently.
• TRDA shares rose 1.2% to $6.95, but Entrada reported a quarterly loss of $1.01 per share and revenue of $0.90 million, missing analyst estimates for both measures.
• Analyst sentiment is mixed, with a consensus rating of “Hold” and a $17.50 target price; institutional investors own 86.39% of the company.

Entrada Therapeutics, Inc. (NASDAQ:TRDA - Get Free Report) Director Kush Parmar sold 10,494 shares of the stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $7.00, for a total transaction of $73,458.00. Following the sale, the director owned 2,836,098 shares in the company, valued at approximately $19,852,686. This trade represents a 0.37% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Kush Parmar also recently made the following trade(s):

• On Monday, August 10th, Kush Parmar sold 92,444 shares of Entrada Therapeutics stock. The shares were sold at an average price of $7.00, for a total value of $647,108.00.
• On Friday, August 7th, Kush Parmar sold 52,317 shares of Entrada Therapeutics stock. The shares were sold at an average price of $6.85, for a total value of $358,371.45.
• On Friday, July 31st, Kush Parmar sold 1,718 shares of Entrada Therapeutics stock. The stock was sold at an average price of $6.85, for a total value of $11,768.30.
• On Thursday, July 30th, Kush Parmar sold 114,756 shares of Entrada Therapeutics stock. The stock was sold at an average price of $6.93, for a total value of $795,259.08.

Entrada Therapeutics Stock Up 1.2%

TRDA stock traded up $0.08 during mid-day trading on Monday, reaching $6.95. The company had a trading volume of 411,770 shares, compared to its average volume of 464,800. Entrada Therapeutics, Inc. has a one year low of $4.93 and a one year high of $16.45. The stock's 50-day simple moving average is $6.86 and its two-hundred day simple moving average is $9.68. The stock has a market capitalization of $270.63 million, a P/E ratio of -1.76 and a beta of -0.26.

Entrada Therapeutics (NASDAQ:TRDA - Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($1.01) earnings per share for the quarter, missing the consensus estimate of ($0.97) by ($0.04). Entrada Therapeutics had a negative net margin of 3,537.73% and a negative return on equity of 57.61%. The firm had revenue of $0.90 million during the quarter, compared to the consensus estimate of $2.32 million. On average, research analysts forecast that Entrada Therapeutics, Inc. will post -4.07 EPS for the current fiscal year.

Hedge Funds Weigh In On Entrada Therapeutics

A number of institutional investors have recently modified their holdings of the company. State of Wyoming bought a new position in Entrada Therapeutics in the 2nd quarter worth $37,000. Russell Investments Group Ltd. grew its holdings in shares of Entrada Therapeutics by 72.7% during the 3rd quarter. Russell Investments Group Ltd. now owns 8,808 shares of the company's stock worth $51,000 after purchasing an additional 3,707 shares in the last quarter. Occudo Quantitative Strategies LP bought a new stake in Entrada Therapeutics in the 2nd quarter valued at $68,000. Jain Global LLC acquired a new position in Entrada Therapeutics in the third quarter worth about $69,000. Finally, IHT Wealth Management LLC bought a new position in shares of Entrada Therapeutics during the 2nd quarter worth approximately $72,000. Institutional investors own 86.39% of the company's stock.

Wall Street Analysts Forecast Growth

TRDA has been the subject of several recent analyst reports. Guggenheim decreased their price objective on shares of Entrada Therapeutics from $20.00 to $17.00 and set a "buy" rating for the company in a report on Monday, June 8th. HC Wainwright lowered shares of Entrada Therapeutics from a "buy" rating to a "neutral" rating in a research note on Friday, May 8th. Weiss Ratings downgraded Entrada Therapeutics from a "sell (d)" rating to a "sell (d-)" rating in a report on Thursday, June 11th. Finally, Roth Capital set a $10.00 price objective on shares of Entrada Therapeutics in a research note on Friday, May 8th. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus target price of $17.50.

Entrada Therapeutics Company Profile

Entrada Therapeutics NASDAQ: TRDA is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company's pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source